Last updated: May 26, 2026
ecutive summary
RETEVMO (selpercatinib) is supplied primarily through a limited number of qualified manufacturing sources for drug substance and drug product, with commercial supply centered on active ingredient and tablet manufacturing that supports Eli Lilly and Company’s marketed SKUs. Patent and exclusivity status do not change the core supplier set because RETEVMO’s supply chain is governed by manufacturing approvals for the marketed dosage forms and by post-approval change history captured in FDA Chemistry, Manufacturing, and Controls (CMC) submissions. No supplier list can be produced here without specific, citable FDA/Orange Book/CIMS manufacturing-site records for RETEVMO’s approved label and each strength, and those records are not provided in the prompt.
Who supplies RETEVMO (selpercatinib) and who manufactures the tablets?
What companies manufacture RETEVMO (selpercatinib) drug product?
Featured snippet answer: The approved manufacturer(s) for RETEVMO tablets are identified in the FDA label for the specific dosage form/strength and in the corresponding FDA drug application records. A supplier roster requires the labeled “Manufactured for” and “Manufactured by” information for each strength.
Where does RETEVMO tablet manufacturing information show up?
- FDA prescribing information (label) “Manufactured for” / “Manufactured by”
- FDA drug approval package CMC (site-specific)
- Orange Book listings and associated application/holder entries (where cross-referenced)
- FDA inspections and facility registration linked to manufacturing lines (not a complete proxy for marketing supply without facility-level mapping)
Who makes RETEVMO selpercatinib drug substance?
Featured snippet answer: The drug substance supplier is defined by the approved manufacturer of record for selpercatinib API in the application’s CMC section. Publicly visible supplier names depend on what the FDA label and approval documents disclose.
Why API suppliers matter for supply continuity
- API is often the constrained node for kinase inhibitors due to multi-step synthesis and impurity control
- Site changes can trigger regulatory reporting and revalidation timelines
- Contract manufacturing terms and tech transfer determine whether back-up capacity exists
Which suppliers support RETEVMO distribution in the US?
How does the US commercial supply chain for RETEVMO work?
Featured snippet answer: US distribution runs through the marketing authorization holder’s commercial operations and approved label manufacturing sites. Supplier changes are mediated through FDA CMC reporting and periodic GMP readiness.
Common commercial patterns for specialty oncology drugs
- Primary US manufacturing site supports initial launches and ongoing replenishment
- Secondary/backup sites support continuity for API supply, bulk fill-finish, and packaging
- Label may list one finished-goods site while API is sourced from different chemical plants
What is RETEVMO Orange Book status and does it affect suppliers?
What Orange Book listings exist for RETEVMO selpercatinib?
Featured snippet answer: Orange Book status and patent listings govern generic and biosimilar entry timing, not the identities of marketing supply manufacturers. Supplier lists come from label and application CMC records.
What to look for when mapping supplier risk to exclusivity
- Patent-expiration-driven generic launch risk can change demand forecasting and safety stock
- CMC change approvals can enable additional sites, reducing supply volatility even under exclusivity
When do RETEVMO exclusivity and patents expire, and what does that imply for generic supply?
When does RETEVMO lose exclusivity?
Featured snippet answer: Generic entry is controlled by Orange Book patents and patent term, plus any regulatory exclusivities tied to the application. That determines entry timing, not which companies currently supply the branded product.
How exclusivity affects downstream supply strategy
- During exclusivity, additional suppliers are mostly about continuity and capacity, not generic competition
- After key dates, generics and authorized distributors attempt to secure manufacturing slots that meet bioequivalence and dissolution specs
What generic entry risks exist for RETEVMO and could they change supplier landscape?
Will generics force new suppliers for selpercatinib tablets?
Featured snippet answer: It will change competition and pricing but does not retroactively re-map branded supplier identities. Separate generic approval and manufacturing sites will emerge for competitor SKUs.
How to assess supplier transitions around launch windows
- Look for abbreviated approval submissions tied to the labeled strengths
- Map ANDA applicant manufacturing sites once approvals begin (site names become visible as approvals progress)
Which companies might be qualified to manufacture RETEVMO-like formulations?
What formulation or process suppliers could support alternatives?
Featured snippet answer: Any CDMO with proven kinase inhibitor tablet manufacturing and approved process control could potentially support new filings, but qualification is specific to product and site.
Technical constraints that narrow CDMO eligibility
- Solid-dose GMP capability for cytotoxic or kinase inhibitor handling
- Stability management for specific polymorph and impurity profiles
- Analytical method validation for dissolution and content uniformity
How strong is RETEVMO’s patent estate, and does it affect supply negotiations?
How does patent strength affect manufacturing capacity planning?
Featured snippet answer: Patent strength affects commercial planning more than it affects near-term branded manufacturing supplier selection. Supply planning is driven by expected demand under exclusivity and by site redundancy requirements.
Typical contract manufacturing consequences
- Demand forecasts influence whether Lilly secures second-source API or second-fills
- Patent milestones influence inventory builds and option exercises in supply contracts
Key Takeaways
- RETEVMO supplier identification requires site-specific, label- and FDA-record-based manufacturing information for each dosage form and strength.
- Patent and Orange Book status drive generic entry timing and litigation exposure, not the current branded supplier roster.
- Without the FDA label manufacturing entries (or equivalent citable FDA CMC records), a factual supplier list for RETEVMO cannot be produced.
FAQs
- How do I find the finished-goods manufacturer listed on the RETEVMO label for each strength?
- Where in FDA records are RETEVMO API manufacturers identified (CMC sections vs label vs inspections)?
- Does RETEVMO’s exclusivity affect CDMO site selection for branded supply?
- What manufacturing site changes typically require FDA CMC reporting for selpercatinib tablets?
- When generic ANDAs for selpercatinib launch, how can I map their manufacturing sites to approved labels?
References (APA)
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration.
